RXi Pharmaceuticals (NASDAQ:RXII) is up 13% premarket on modestly higher volume in response to its announcement of positive results from a consumer testing program assessing the ability of RXI-231 to reduce skin pigmentation caused by exposure to UV light.
The first two RXi Pharmaceuticals of RXI-231studies in volunteers determined that the RXI-231 gel formulation does not cause irritation and sensitization when applied to the skin. A third study investigated the potential of RXI-231 to impact a skin melanin content (pigmentation) increase induced by UV exposure, as measured by narrow-band reflectance spectroscopy, in a study design similar to one well documented in peer-reviewed journal articles and used by various cosmetic companies. Specific spectroscopic results – known to correlate well with skin melanin content – show that application with RXI-231 containing gel, as compared to vehicle gel, can reduce a change of skin tone triggered by UV.
RXi Pharmaceuticals’ RXI-231 targets TYR, a key enzyme involved in the synthesis of melanin. Initial results with RXI-231 resulted in a visible reduction of pigmentation in 3-dimensional reconstituted human epidermal culture. Further testing showed a decrease in melanin content in cultured primary human melanocytes lasting for at least one week after a single dose. RXi has developed a gel formulation that allows sd-rxRNA based cosmetic ingredients, which are relatively large (9-12 kDa) and negatively charged, to penetrate into the skin layers where the melanin producing cells reside.
We want you to join our community
Benefits of signing up for a FREE membership now:
-No more costly delays in waiting for material
-Dozens of publications per week, including news coverage, earnings commentary, analysis, politics, and more
-Access to special guest contributions, including from WSJ, CNBC, and prolific SA authors
–Ability to comment on articles
–Access to our weekly newsletter
-Publish your own opinion/analysis
…..and FREE access to our upcoming paid content for life
Thank you for your readership, and for your loyalty.
Not interested? We understand. However, you will miss out on the insights we have provided over the years, that helped drive us to the NUMBER ONE AUTHOR on long ideas on the Seeking Alpha Platform,